Clinical trial
Lapatinib in Metastatic Breast Cancer Resistant to Hormone Therapy
NCT00225758 · Gary Schwartz, Other · Terminated
Key facts
| NCT number | NCT00225758 |
|---|---|
| Title | Lapatinib in Metastatic Breast Cancer Resistant to Hormone Therapy |
| Official title | Lapatinib in Endocrine-Resistant Metastatic Breast Cancer |
| Lead sponsor | Gary Schwartz, Other |
| Collaborators | University of Colorado, Denver North Shore University Hospital |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Breast Cancer |
| Intervention type | Drug |
| Interventions | Lapatinib |
| Enrollment | 27 |
| Start date | Jan 1, 2006 |
| Primary completion | Oct 1, 2011 |
| Completion | Oct 1, 2011 |
| First posted | Sep 26, 2005 |
| Last update posted | Jul 27, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: